QuidelOrtho Co. (NASDAQ:QDEL - Get Free Report) shares reached a new 52-week low on Wednesday . The company traded as low as $27.35 and last traded at $27.79, with a volume of 1406704 shares. The stock had previously closed at $28.58.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the company. UBS Group raised their price target on QuidelOrtho from $43.00 to $45.00 and gave the stock a "neutral" rating in a research report on Thursday, February 13th. StockNews.com cut QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. JPMorgan Chase & Co. decreased their price objective on shares of QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating for the company in a report on Monday, April 21st. Finally, Royal Bank of Canada reduced their price target on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $46.83.
Get Our Latest Research Report on QDEL
QuidelOrtho Trading Down 6.5 %
The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22. The company has a market cap of $1.75 billion, a P/E ratio of -0.86 and a beta of 0.13. The business's 50-day moving average price is $32.07 and its 200 day moving average price is $38.37.
QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. As a group, analysts expect that QuidelOrtho Co. will post 2.3 earnings per share for the current year.
Institutional Trading of QuidelOrtho
A number of institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. boosted its holdings in shares of QuidelOrtho by 19.6% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,238,826 shares of the company's stock valued at $500,690,000 after purchasing an additional 1,840,667 shares in the last quarter. Invesco Ltd. raised its stake in QuidelOrtho by 71.7% during the fourth quarter. Invesco Ltd. now owns 3,447,446 shares of the company's stock worth $153,584,000 after acquiring an additional 1,439,293 shares in the last quarter. Norges Bank acquired a new stake in shares of QuidelOrtho in the 4th quarter valued at approximately $34,171,000. Vanguard Group Inc. grew its holdings in shares of QuidelOrtho by 12.6% during the 4th quarter. Vanguard Group Inc. now owns 6,817,412 shares of the company's stock valued at $303,716,000 after purchasing an additional 764,900 shares during the last quarter. Finally, Segall Bryant & Hamill LLC increased its position in QuidelOrtho by 143.9% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,046,649 shares of the company's stock worth $46,628,000 after purchasing an additional 617,592 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors.
About QuidelOrtho
(
Get Free Report)
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
Featured Articles
Before you consider QuidelOrtho, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.
While QuidelOrtho currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
